1Urashima M, Ogata A, Chauhan D, et al. Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells.Blood, 1996,87:1928-1938. 被引量：1
2Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B.Blood, 1996,87:1104-1112. 被引量：1
3Palombella VJ, Rando OJ, Goldberg AL, et al. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B.Cell, 1994,78:773-785. 被引量：1
4Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.Cancer Res, 2001,61:3071-3076. 被引量：1
5Masdehors P, Omura S, Merle-Beral H, et al. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin.Br J Haematol, 1999,105:752-757. 被引量：1
6Damiano JS, Cress AE, Hazlehurst LA, et al. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.Blood, 1999,93:1658-1667. 被引量：1
7Berenson JR. New advances in the biology and treatment of myeloma bone disease.Semin Hematol, 2001,38 Suppl 3:15-20. 被引量：1
8Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.Blood, 2000, 96:2943-2950. 被引量：1
9Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood, 1999, 93:3064-3073. 被引量：1
10Laird AD, Vajkoczy P, Shawver LK, et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.Cancer Res, 2000, 60:4152-4160. 被引量：1
